| Stage | NPK | % of rev | AXON | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $147M | 100.00% | $904M | 100.00% | AXON ×6.17 |
| Gross profit | $29M | 19.47% | $546M | 60.42% | AXON +40.9pp |
| Operating income | $19M | 13.24% | $47M | 5.17% | NPK +8.1pp |
| Pre-tax income | $20M | 13.79% | $33M | 3.61% | NPK +10.2pp |
| Net income | $16M | 10.82% | $29M | 3.25% | NPK +7.6pp |
| Stage | NPK | AXON | Gap · A − B |
|---|---|---|---|
| Revenue | $147M100.00% | $904M100.00% | AXON ×6.17 |
| Gross profit | 19.47%$29M | 60.42%$546M | AXON +40.9pp |
| Operating income | 13.24%$19M | 5.17%$47M | NPK +8.1pp |
| Pre-tax income | 13.79%$20M | 3.61%$33M | NPK +10.2pp |
| Net income |
| 10.82%$16M |
| 3.25%$29M |
| NPK +7.6pp |
No disclosed counterparties: AXON.
None